Original articleMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Section snippets
Study Population
Details of the design and methods for CATT have been published previously.3 Parameters used to determine the participants’ morphologic features at baseline and 52 weeks are summarized. A total of 1185 subjects were enrolled by 43 US clinical centers between February 2008 and December 2009. Only 1 eye per subject, the study eye, was treated as a part of the clinical trial. Inclusion criteria included subject age ≥50 years, presence of previously untreated active CNV secondary to AMD in the study
Presence and Type of Fluid on Optical Coherence Tomography Over Time
At baseline, all eligible eyes had at least 1 type of fluid, reflecting active CNV. The distribution of each fluid type at baseline was similar among the 4 treatment groups (Fig 1A–D). A high proportion of eyes had both SRF (83.8%) and IRF (76.7%). Sub-RPE fluid was present in approximately half (53.7%) of the eyes.
After anti-VEGF therapy, in all treatment groups, the proportion of eyes with fluid of any type (intraretinal, subretinal, or sub-RPE fluid) decreased markedly (Fig 1A). The largest
Discussion
In this study, several morphologic features determined on OCT, FA, and FP were significantly affected by intravitreal anti-VEGF therapy and had a significant relationship with VA. In particular, anti-VEGF treatment, regardless of drug and regimen, generally caused rapid and sustained reduction in macular fluid and thickness, stabilized lesion growth, reduced vascular leakage, and normalized retinal anatomy. Furthermore, presence of IRF, abnormally thin or thick retinas, larger CNV area, and
References (13)
- et al.
Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
Ophthalmology
(2012) - et al.
Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration
Ophthalmology
(2013) - et al.
Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials
Ophthalmology
(2012) - et al.
A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol
Am J Ophthalmol
(2003) - et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006)
Cited by (231)
Age-related macular degeneration
2023, The LancetTowards a better understanding of non-exudative choroidal and macular neovascularization
2023, Progress in Retinal and Eye ResearchCitation Excerpt :Sub-retinal hyperreflective material is characterized by the evidence of hyperreflective material in the subretinal space detected through OCT, which has been correlated with a poor visual outcome in neovascular AMD (Balaskas et al., 2019; Jaffe et al., 2013; Keane et al., 2008; Willoughby et al., 2015). Sub-RPE fluid develops in the context of RPE separation or detachment from the BrM and can also have prognostic significance like IRF and SRF (Chaudhary et al., 2021; Jaffe et al., 2013; Spaide et al., 2020). The CATT and HARBOR trials and other more recent studies have shown that sub-RPE fluid present at the final outcome visit correlates with a more favorable anatomic and visual outcome (Fang et al., 2021).
Manuscript no. 2012-1815.
∗Group members listed in Appendix 1 (available at http://aaojournal.org).
Financial Disclosure(s): The author(s) have made the following disclosure(s): G.J.J. has a consultancy relationship with Heidelberg Engineering and active or pending grants from Regeneron. C.A.T. has a consultancy relationship with Physical Sciences Inc.; active or pending grants from Genentech, Bioptigen, and Physical Sciences Inc.; a patent pending for OCT analysis technology related to analysis for AMD; and royalties from Alcon Laboratories for ophthalmic surgical technologies. G.J.J. and C.A.T.’s institution receives money for these relationships. The other members of the writing committee have no financial relationships to declare.
Supported by cooperative agreements U10 EY017823, U10 EY017825, U10 EY017826, and U10 EY017828 from the National Eye Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. The funding organization participated in the design and conduct of the study and review of the manuscript.
ClinicalTrials.gov number NCT00593450.
- ∗
The credit roster for the CATT Research Group is provided in Appendix 1, available at http://aaojournal.org.